AU2014351796B2 - Preparations and methods for treating a GD2 positive cancer - Google Patents

Preparations and methods for treating a GD2 positive cancer Download PDF

Info

Publication number
AU2014351796B2
AU2014351796B2 AU2014351796A AU2014351796A AU2014351796B2 AU 2014351796 B2 AU2014351796 B2 AU 2014351796B2 AU 2014351796 A AU2014351796 A AU 2014351796A AU 2014351796 A AU2014351796 A AU 2014351796A AU 2014351796 B2 AU2014351796 B2 AU 2014351796B2
Authority
AU
Australia
Prior art keywords
treatment
antibody
patient
preparation
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014351796A
Other languages
English (en)
Other versions
AU2014351796A1 (en
AU2014351796A2 (en
Inventor
Isabel Klier
Ruth LADENSTEIN
Hans Loibner
Oliver MUTSCHLECHNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeiron Biologics AG
Original Assignee
Apeiron Biologics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13193953.0A external-priority patent/EP2875827A1/en
Priority claimed from CA2834000A external-priority patent/CA2834000A1/en
Priority claimed from US14/182,776 external-priority patent/US10294305B2/en
Application filed by Apeiron Biologics AG filed Critical Apeiron Biologics AG
Publication of AU2014351796A1 publication Critical patent/AU2014351796A1/en
Publication of AU2014351796A2 publication Critical patent/AU2014351796A2/en
Application granted granted Critical
Publication of AU2014351796B2 publication Critical patent/AU2014351796B2/en
Priority to AU2020203346A priority Critical patent/AU2020203346A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2014351796A 2013-11-21 2014-11-21 Preparations and methods for treating a GD2 positive cancer Active AU2014351796B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203346A AU2020203346A1 (en) 2013-11-21 2020-05-22 Preparations And Methods For Treating A GD2 Positive Cancer

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201314086696A 2013-11-21 2013-11-21
US14/086,696 2013-11-21
CA2834000 2013-11-21
EP13193953.0 2013-11-21
EP13193953.0A EP2875827A1 (en) 2013-11-21 2013-11-21 Preparations and methods for treating a GD2 positive cancer
CA2834000A CA2834000A1 (en) 2013-11-21 2013-11-21 Method for treating a gd2 positive cancer
US14/182,776 US10294305B2 (en) 2012-06-18 2014-02-18 Method for treating a GD2 positive cancer
US14/182,776 2014-02-18
PCT/EP2014/075315 WO2015075194A1 (en) 2013-11-21 2014-11-21 Preparations and methods for treating a gd2 positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203346A Division AU2020203346A1 (en) 2013-11-21 2020-05-22 Preparations And Methods For Treating A GD2 Positive Cancer

Publications (3)

Publication Number Publication Date
AU2014351796A1 AU2014351796A1 (en) 2016-05-26
AU2014351796A2 AU2014351796A2 (en) 2016-08-11
AU2014351796B2 true AU2014351796B2 (en) 2020-02-27

Family

ID=53179006

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014351796A Active AU2014351796B2 (en) 2013-11-21 2014-11-21 Preparations and methods for treating a GD2 positive cancer
AU2020203346A Abandoned AU2020203346A1 (en) 2013-11-21 2020-05-22 Preparations And Methods For Treating A GD2 Positive Cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203346A Abandoned AU2020203346A1 (en) 2013-11-21 2020-05-22 Preparations And Methods For Treating A GD2 Positive Cancer

Country Status (19)

Country Link
US (3) US10995147B2 (OSRAM)
EP (2) EP3620173A1 (OSRAM)
JP (2) JP6693873B2 (OSRAM)
AU (2) AU2014351796B2 (OSRAM)
CA (1) CA2930285A1 (OSRAM)
CY (1) CY1122508T1 (OSRAM)
DK (1) DK3071220T3 (OSRAM)
EA (1) EA201691055A1 (OSRAM)
ES (1) ES2768649T3 (OSRAM)
HR (1) HRP20200128T1 (OSRAM)
HU (1) HUE047920T2 (OSRAM)
LT (1) LT3071220T (OSRAM)
NZ (1) NZ720273A (OSRAM)
PL (1) PL3071220T3 (OSRAM)
PT (1) PT3071220T (OSRAM)
RS (1) RS59817B1 (OSRAM)
SI (1) SI3071220T1 (OSRAM)
SM (1) SMT202000027T1 (OSRAM)
WO (1) WO2015075194A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
JP6693873B2 (ja) 2013-11-21 2020-05-13 アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ Ｇｄ２陽性がんを処置するための製剤および方法
RU2663104C1 (ru) * 2017-07-13 2018-08-01 Общество с ограниченной ответственностью "Реал Таргет" Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей
SG11202002581WA (en) 2017-09-21 2020-04-29 Umc Utrecht Holding Bv Anti-gd2 antibody for the treatment of neuroblastoma
MX2023000384A (es) * 2020-07-06 2023-06-16 Eusa Pharma Uk Ltd Metodo para tratar un cancer positivo para gd2.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
EP2325205A3 (en) 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
CA2510180C (en) 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
AR056138A1 (es) 2005-10-21 2007-09-19 Hoffmann La Roche Procedimiento para la expresion recombinante de un polipeptido
EP1916257A1 (en) 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
AU2009267113A1 (en) 2008-06-30 2010-01-07 Morphotek, Inc. Anti-GD2 antibodies and methods and uses related thereto
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
JP5623999B2 (ja) 2010-08-31 2014-11-12 パナソニック株式会社 電子装置
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
US9777068B2 (en) 2012-06-18 2017-10-03 Apeiron Biologics Ag Method for treating a GD2 positive cancer
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
JP6693873B2 (ja) 2013-11-21 2020-05-13 アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ Ｇｄ２陽性がんを処置するための製剤および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUSHNER B H ET AL, JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, (2001-11-15), vol. 19, no. 22, ISSN 0732-183X, pages 4189 - 4194 *
MURRAY J L ET AL, JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, (1994-01-01), vol. 12, no. 1, ISSN 0732-183X, pages 184 - 193 *
R. HANDGRETINGER ET AL, EUROPEAN JOURNAL OF CANCER, (1995-01-01), vol. 31, no. 2, doi:10.1016/0959-8049(94)00413-Y, ISSN 0959-8049, pages 261 - 267 *

Also Published As

Publication number Publication date
SMT202000027T1 (it) 2020-03-13
HUE047920T2 (hu) 2020-05-28
JP6693873B2 (ja) 2020-05-13
SI3071220T1 (sl) 2020-03-31
CA2930285A1 (en) 2015-05-28
JP7139293B2 (ja) 2022-09-20
DK3071220T3 (da) 2020-02-10
JP2016539122A (ja) 2016-12-15
CY1122508T1 (el) 2021-05-05
US20240158530A1 (en) 2024-05-16
AU2020203346A1 (en) 2020-06-11
US11492412B2 (en) 2022-11-08
ES2768649T3 (es) 2020-06-23
HK1223039A1 (en) 2017-07-21
AU2014351796A1 (en) 2016-05-26
AU2014351796A2 (en) 2016-08-11
NZ720273A (en) 2022-02-25
WO2015075194A1 (en) 2015-05-28
EP3620173A1 (en) 2020-03-11
EA201691055A1 (ru) 2016-11-30
LT3071220T (lt) 2020-02-25
HRP20200128T1 (hr) 2020-05-15
EP3071220A1 (en) 2016-09-28
PL3071220T3 (pl) 2020-05-18
EP3071220B1 (en) 2019-12-25
JP2019218359A (ja) 2019-12-26
US10995147B2 (en) 2021-05-04
PT3071220T (pt) 2020-02-03
US20200332021A1 (en) 2020-10-22
RS59817B1 (sr) 2020-02-28
US20210221909A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
US20230340148A1 (en) Method for treating a gd2 positive cancer
US11492412B2 (en) Preparations and methods for treating a GD2 positive cancer
US9777068B2 (en) Method for treating a GD2 positive cancer
US11597775B2 (en) Preparations and methods for treating a GD2 positive cancer
CN113474004A (zh) 用于治疗肿瘤的包含抗cd19抗体和自然杀伤细胞的药物组合
CA2834000A1 (en) Method for treating a gd2 positive cancer
EP2875827A1 (en) Preparations and methods for treating a GD2 positive cancer
HK40022685A (en) Preparations and methods for treating a gd2 positive cancer
HK1223039B (en) Preparations for treating a gd2 positive cancer
EA043975B1 (ru) Препараты и способы лечения gd2-положительного рака

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 JUL 2016

FGA Letters patent sealed or granted (standard patent)
GD Licence registered

Name of requester: EUSA PHARMA (UK) LIMITED